Answers are grounded in this paper and cite their sources.
Evaluates HER2-ultralow prevalence in breast cancer, suggesting need for training to improve scoring accuracy.
Context.—: Prevalence data of human epidermal growth factor receptor 2 (HER2)-ultralow (immunohistochemistry [IHC] 0 with membrane staining in ≤10% of cells; HER2 IHC 0+) breast cancer are limited. Objective.—: To evaluate the proportion of HER2-ultralow among metastatic breast cancer samples originally scored HER2 IHC 0 (with or absent membrane staining) and 1+ and to evaluate interobserver concordance between pathologists' rescores and original scores. Design.—: Whole slide images (WSIs) from metastatic breast cancer biopsy specimens originally scored HER2 IHC 0 (with or absent membrane staining) and 1+ were rescored as HER2 IHC 0 absent membrane staining, IHC 0+ (with membrane staining), IHC 1+, or IHC 2+ by 3 pathologists. Each pathologist performed 2 blinded readings (washout period of ≥2 weeks). Results.—: Of the 246 IHC 0 WSIs, 78 (31.7%), 75 (30.5%), and 86 (35.0%) were rescored as HER2 IHC 0 absent membrane staining, 0+, and 1+, respectively. Of the 138 IHC 1+ WSIs, 3 (2.2%), 10 (7.2%), 117 (84.8%), and 6 (4.3%) were rescored as IHC 0 absent membrane staining, 0+, 1+, and 2+, respectively. Interobserver concordance was substantial (overall percentage agreement [OPA; 95% CI], 86.7% [82.9%-90.0%]; Cohen κ [95% CI], 0.781 [0.726-0.835]) to moderate (OPA [95% CI], 62.0% [59.9%-66.9%]; Cohen κ [95% CI], 0.441 [0.379-0.502]). Agreement between pathologists' consensus scores and original scores was moderate (OPA [95% CI], 72.1% [67.3%-76.5%]; Cohen κ [95% CI], 0.461 [0.381-0.541]). Conclusions.—: Scoring discrepancies highlight the potential need/benefits of training for evaluating HER2-low/HER2-ultralow cases in metastatic breast cancer, which could improve consistency in HER2 scoring by pathologists.
No takes yet. Share an insight, caveat, or question.
Krishnamurthy et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: